Best Life Sciences Companies in North District, Israel
The 49 best Life Sciences companies in North District, Israel in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Kaiima.
Our analysis of 50 Life Sciences companies
$2.2b in tracked funding; 75% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2024.
Ranked: Best Life Sciences companies in North District
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Kaiima Developer of plant genetics and breeding technology | $91M | 155 mo ago | Series C | Doron Gal ex-CEO | 2007 | — | — | 1 partnership |
| 2 | BioSight Developer of therapeutics for oncology & hematological disorders | $59M | 68 mo ago | Acquired | — | 2000 | — | 90 patents Prodrug conjugates of cytarabine with amino acids for targeted cancer chemotherapy | — |
| 3 | Tisbury Pharmaceuticals Small fusion molecule drug to treat open angle glaucoma | $32M | 110 mo ago | Deadpooled | Salzman Andrew Founder | 2015 | — | — | — |
| 4 | Igentify Provider of digital healthcare solutions and screening genetic tests | $16M | 82 mo ago | Series A | — | 2016 | WordPressMySQLPHP+21 | 11 patents Adaptive speech gap modulation technology and distributed genomic data storage solutions. | — |
| 5 | Via Surgical Tran fascial suture fixation device for hernia repair | $7M | 64 mo ago | Series B | — | 2012 | — | 57 patents Provides variable-depth surgical fastening and suturing devices for tissue closure. | — |
| 6 | Metallo Therapy Tumor-targeted contrast agents based on surface-modified gold nanoparticles | $4M | 183 mo ago | Deadpooled | Amal Ayoub Founder & CEO | 2010 | — | 8 patents Surface-modified heavy‑metal nanoparticle drug delivery systems for therapeutic applications | — |
| 7 | Novotyr IGF1R inhibitors for the treatment of cancer | $4M | 217 mo ago | Deadpooled | Hadas Reuveni CEO | 2005 | — | — | — |
| 8 | EXOSOMM Developer of a novel food product that contains patent-based milk exosomes | $100K | 39 mo ago | Seed | Netta Granot Co-Founder & CEO | 2021 | — | — | — |
| 9 | Protalix BioTherapeutics Developer of recombinant proteins through plant cell-based expression system | — | 77 mo ago | Public | — | 1993 | DrupalPHPAmazon Web Services+17 | — | 1 launch |
Top 9 Life Sciences companies in North District
#1
Acquired · Karmiel, North District · founded 2000 · 10 employees$59Mraised▾
Developer of therapeutics for oncology & hematological disorders. The company's lead product is aspacytarabine (BST-236) an anti-metabolite for Adult acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS).
- Dec 2020Series C$27M
- Mar 2020Series C$19M
- May 2016Series A$13M
#2
Seed · Safed, North District · founded 2021$100Kraised▾
Developer of a novel food product that contains patent-based milk exosomes. It offers nutritional solutions for Inflammatory Bowel Diseases (IBD) that have a therapeutic and anti-inflammatory effect on colitis.
- May 2023Seed$100K
#3
Series B · Amirim, North District · founded 2012 · 9 employees$7Mraised▾
Tran fascial suture fixation device for hernia repair. It provides a medical device intended for hernia repair and additional surgical procedures. It has developed FasTouch system to provide deployable transfascial suture fixation for mesh adheres to abdominal walls during the crucial first few weeks post-surgery for healing to take place.
- Mar 2021Series B—
- Feb 2016Series A$6M
- Jul 2012Seed$1M
#4
Series A · Ramat Yishai, North District · founded 2016 · 66 employees$15.5Mraised▾
Igentify is a biomedical informatics company providing preventative healthcare through genomic products and services. It also offers electronic documentation, e-consenting forms and educational clips for the patients. It has developed its first product called FamilyFirst is an Expanded Carrier Screening test adapted to discover diseases and mutations common to the Israeli population of all ethnic groups and origins. The test requires a DNA sample from the cheek lining and is made available across authorized clinics in Israel. Claims that the test screens for over 850 mutations and 260 hereditary diseases to help in better pregnancy planning.
- Sep 2019Series A$10.5M
- Aug 2019Grant (prize money)$55.4K
#5
Series C · Tiberias, North District · founded 2007 · 24 employees$91Mraised▾
Developer of a genetic and breeding technology designed to improve plant productivity. The company's platform focuses on the development of elite castor bean hybrids for the global market and crop productivity, enabling farmers to increase the production of their crops.
#6
Deadpooled · Safed, North District · founded 2015$32Mraised▾
Tisbury Pharmaceuticals is a pre-clinical stage company focused on the developing therapeutics for primary open angle glaucoma. Its clinical candidate R-801 was licensed from its founding company Radikal Therapeutics (RTX). It is constructed by the fusion of 2 pharmacophores, a K+-ATP channel activating moiety that activates the ischemic preconditioning (IPC) response, and a pyrrolidine nitroxide moiety that serves as a mimetic of catalase and superoxide dismutase. The candidate accelerates flow via the trabecular meshwork redox catalysis and K+-ATP channel activation. The candidate maintains a strong IP and claims to has shown no apparent side-effects in its trials. Based in Israel, it has a US office at Beverly, MA.
- Jun 2017Series A$32M
#7
Deadpooled · Nof HaGalil, North District · founded 2010$4Mraised▾
Developer of a therapy designed to treat cancer. The company's brachytherapy technology delivers nano-liposomes containing stabilized gold nano-particles and water-soluble gold complexes to accumulate in tumor cells, enabling patients to treat and diagnose cervical, prostate, breast and skin cancers.
#8
Deadpooled · Qiryat Shemona, North District · founded 2005$3.5Mraised▾
Novotyr Therapeutics was developing small molecule drugs primarily for the treatment of cancer. It had developed inhibitors of an insulin-like growth factor receptor (IG1FR) for the treatment of cancer. The company has received 6 patents for the discovered small molecules which act as modulators of protein kinase signaling. As of December 2016, the company appears to be closed.
- Jun 2008Series A$1M
- Mar 2005Seed—
#9
Public · Karmiel, North District · founded 1993 · 197 employees—raised▾
Developer of recombinant proteins through a plant cell-based expression system. Using ProCellEx, Protalix is focused on the development and commercialization of a proprietary pipeline of novel and biosimilar proteins. It markets ELELYSO, which is a plant cell-expressed form of the glucocerebrosidase (GCD) enzyme for patients with Type 1 Gaucher disease. Also developing recombinant proteins for Fabry disease, immune and inflammatory diseases, and Cystic Fibrosis.
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Biotechnology is moving in Israel
A read on the academic research around Biotechnology — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 267 Israel-affiliated papers.
- Ministry of Agriculture118
- Hebrew University of Jerusalem29
- Agricultural Research Organization25
- Tel Aviv University21
- Ben-Gurion University of the Negev19
- Mitochondrion1→5
- Gene1→18
- Plant disease resistance1→7
- Resistance (ecology)2→6
- Agriculture3→6
Where biotechnology is researched across Israel
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.